4.6 Review

Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6

期刊

ALZHEIMERS RESEARCH & THERAPY
卷 13, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s13195-021-00875-8

关键词

Brain Health Services; Dementia; Aging; Alzheimer's disease; Prevention; Dementia risk; Risk reduction

资金

  1. Swiss National Science Foundation [IZSEZ0_193593]
  2. European Research Council [804371]
  3. Academy of Finland [287490, 294061, 319318, 305810, 317465]
  4. Yrjo Jahnsson Foundation
  5. Finnish Cultural Foundation (Finland)
  6. Alzheimerfonden
  7. Region Stockholm ALF (Sweden)
  8. EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU): European Prevention of Alzheimer's Dementia consortium (EPAD) [115736]
  9. Joint Programme Neurodegenerative Disease Research (EURO-FINGERS)
  10. Knut and Alice Wallenberg Foundation
  11. EU-EFPIA Innovative Medicines Initiatives 2 Joint Undertaking (IMI 2 JU): Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) [115952]
  12. Swiss National Science Foundation: Brain connectivity and metacognition in persons with subjective cognitive decline (COSCODE): correlation with clinical features and in vivo neuropathology [320030_182772]
  13. Swedish Research Council
  14. Center for Innovative Medicine (CIMED) at Karolinska Institutet, Region Stockholm (ALF, NSV)
  15. Stiftelsen Stockholms Sjukhem
  16. Konung Gustaf V:s och Drottning Victorias Frimurarstiftelse
  17. Swedish Research Council for Health, and Working Life and Welfare (FORTE)
  18. Academy of Finland (AKA) [305810, 305810] Funding Source: Academy of Finland (AKA)
  19. Swiss National Science Foundation (SNF) [IZSEZ0_193593] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

Despite the lack of established prevention strategies, there have been multidomain dementia prevention trials targeting various risk factors and disease mechanisms. This suggests the potential for precision risk reduction strategies through Brain Health Services, but more research is needed to determine the effectiveness and implementation of such interventions, especially in low- and middle-income countries.
Although prevention of dementia and late-life cognitive decline is a major public health priority, there are currently no generally established prevention strategies or operational models for implementing such strategies into practice. This article is a narrative review of available evidence from multidomain dementia prevention trials targeting several risk factors and disease mechanisms simultaneously, in individuals without dementia at baseline. Based on the findings, we formulate recommendations for implementing precision risk reduction strategies into new services called Brain Health Services. A literature search was conducted using medical databases (MEDLINE via PubMed and SCOPUS) to select relevant studies: non-pharmacological multidomain interventions (i.e., combining two or more intervention domains), target population including individuals without dementia, and primary outcomes including cognitive/functional performance changes and/or incident cognitive impairment or dementia. Further literature searches covered the following topics: sub-group analyses assessing potential modifiers for the intervention effect on cognition in the multidomain prevention trials, dementia risk scores used as surrogate outcomes in multidomain prevention trials, dementia risk scores in relation to brain pathology markers, and cardiovascular risk scores in relation to dementia. Multidomain intervention studies conducted so far appear to have mixed results and substantial variability in target populations, format and intensity of interventions, choice of control conditions, and outcome measures. Most trials were conducted in high-income countries. The differences in design between the larger, longer-term trials that met vs. did not meet their primary outcomes suggest that multidomain intervention effectiveness may be dependent on a precision prevention approach, i.e., successfully identifying the at-risk groups who are most likely to benefit. One such successful trial has already developed an operational model for implementing the intervention into practice. Evidence on the efficacy of risk reduction interventions is promising, but not yet conclusive. More long-term multidomain randomized controlled trials are needed to fill the current evidence gaps, especially concerning low- and middle-income countries and integration of dementia prevention with existing cerebrovascular prevention programs. A precision risk reduction approach may be most effective for dementia prevention. Such an approach could be implemented in Brain Health Services.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据